Search Results - "Salpeter, S"

Refine Results
  1. 1

    Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus by Salpeter, S, Greyber, E, Pasternak, G, Salpeter, E

    Published in Cochrane database of systematic reviews (01-01-2006)
    “…Metformin is an oral anti-hyperglycemic agent used in the treatment of type 2 diabetes mellitus. The results of the UK Prospective Diabetes Study indicate that…”
    Get more information
    Journal Article
  2. 2

    Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women by Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., Salpeter, E. E.

    Published in Diabetes, obesity & metabolism (01-09-2006)
    “…Aim:  To quantify the effects of hormone‐replacement therapy (HRT) on components of the metabolic syndrome in postmenopausal women. Methods:  Comprehensive…”
    Get full text
    Journal Article
  3. 3

    A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression by Salpeter, S J, Pozniak, Y, Merquiol, E, Ben-Nun, Y, Geiger, T, Blum, G

    Published in Oncogene (10-12-2015)
    “…Although cysteine cathepsins have been identified as key regulators of cancer growth, their specific role in tumor development remains unclear. Recent studies…”
    Get full text
    Journal Article
  4. 4

    Cardioselective beta-blockers for chronic obstructive pulmonary disease by Salpeter, S, Ormiston, T, Salpeter, E

    Published in Cochrane database of systematic reviews (19-10-2005)
    “…Beta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the…”
    Get more information
    Journal Article
  5. 5

    Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus by Salpeter, S, Greyber, E, Pasternak, G, Salpeter, E

    “…Metformin is an oral anti-hyperglycemic agent used in the treatment of type 2 diabetes mellitus. The results of the UK Prospective Diabetes Study indicate that…”
    Get more information
    Journal Article
  6. 6

    Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis by Salpeter, S.R, Ormiston, T.M, Salpeter, E.E, Poole, P.J, Cates, C.J

    Published in Respiratory medicine (01-10-2003)
    “…Beta-blocker therapy has a mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative…”
    Get full text
    Journal Article
  7. 7

    Cardioselective beta-blockers for chronic obstructive pulmonary disease by Salpeter, S S, Ormiston, T, Salpeter, E, Poole, P, Cates, C

    “…Beta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the…”
    Get more information
    Journal Article
  8. 8

    Cardioselective beta-blocker use in patients with reversible airway disease by Salpeter, S, Ormiston, T, Salpeter, E

    “…Beta-blocker therapy has mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative…”
    Get more information
    Journal Article
  9. 9

    Mathematical Model for the Epidemiology of Tuberculosis, with Estimates of the Reproductive Number and Infection-Delay Function by Salpeter, Edwin E., Salpeter, Shelley R.

    Published in American journal of epidemiology (15-02-1998)
    “…The authors used epidemiologic data on tuberculosis to construct a model for the time delay from initial latent infection to active disease, when infection…”
    Get full text
    Journal Article
  10. 10

    Determinants of pancreatic β-cell regeneration by Khalaileh, A, Gonen-Gross, T, Magenheim, J, Nir, T, Porat, S, Salpeter, S, Stolovich-Rain, M, Swisa, A, Weinberg, N, Dor, Y

    Published in Diabetes, obesity & metabolism (01-11-2008)
    “…Recent studies have revealed a surprising plasticity of pancreatic β-cell mass. β-cell mass is now recognized to increase and decrease in response to…”
    Get full text
    Journal Article
  11. 11

    Monitored Isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age : A risk-benefit and cost-effectiveness analysis by SALPETER, S. R, SANDERS, G. D, SALPETER, E. E, OWENS, D. K

    Published in Annals of internal medicine (15-12-1997)
    “…Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis. Current guidelines recommend withholding this prophylaxis…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis by Salpeter, S R

    Published in The Western journal of medicine (01-11-1993)
    “…Isoniazid chemoprophylaxis has long been known to be a highly effective means of preventing silent tuberculous infections from spreading to active disease…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Tuberculosis chemoprophylaxis by Salpeter, S

    Published in The Western journal of medicine (01-10-1992)
    “…The incidence of tuberculosis in the United States, after decreasing for many years, has recently begun to climb at an alarming rate. This rise is due mainly…”
    Get full text
    Journal Article
  17. 17

    Calcium-Channel Blockade and Hypertension by Salpeter, S

    Published in The New England journal of medicine (29-07-1999)
    “…To the Editor: Tuomilehto and colleagues present a post hoc analysis (March 4 issue) 1 of a trial of nitrendipine-based treatment for older patients with…”
    Get full text
    Journal Article
  18. 18

    Organization of Acetylcholine Receptors in Quick-Frozen, Deep-Etched, and Rotary-Replicated Torpedo Postsynaptic Membrane by Heuser, J. E., Salpeter, S. R.

    Published in The Journal of cell biology (01-07-1979)
    “…The receptor-rich postsynaptic membrane of the elasmobranch electric organ was fixed by quick-freezing and then viewed by freeze-fracture, deep-etching, and…”
    Get full text
    Journal Article
  19. 19
  20. 20